Carbamazepine (Carbatrol, Equetro, Tegretol) — 2026 Medicare Part D coverage
carbamazepine — sold as Carbatrol, Equetro, Tegretol: 21 forms appear in Medicare Part D formularies for 2026. This page reports what plans filed with CMS; it does not recommend a plan.
Which plans in your county cover carbamazepine?
Pick a county to see every Medicare Advantage plan filed there and every stand-alone Part D plan in its region, with this drug's tier, restrictions and tier cost sharing.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.
Forms and strengths in 2026 formularies
| Form | Formularies listing it | Most common tier | PA | ST | QL |
|---|---|---|---|---|---|
| carBAMazepine 100 MG 12HR Extended Release Oral Tablet generic · RxCUI 199378 | 328 (100%) | 2 | 0 | 0 | 2 |
| carBAMazepine 100 MG Chewable Tablet generic · RxCUI 308973 | 328 (100%) | 2 | 0 | 0 | 2 |
| carBAMazepine 100 MG in 5 mL Oral Suspension generic · RxCUI 308976 | 328 (100%) | 4 | 0 | 0 | 2 |
| carBAMazepine 200 MG 12HR Extended Release Oral Tablet generic · RxCUI 402505 | 328 (100%) | 4 | 0 | 0 | 2 |
| carBAMazepine 200 MG Oral Tablet generic · RxCUI 308979 | 328 (100%) | 2 | 0 | 0 | 2 |
| carBAMazepine 400 MG 12HR Extended Release Oral Tablet generic · RxCUI 402506 | 328 (100%) | 4 | 0 | 0 | 2 |
| carBAMazepine 100 MG 12HR Extended Release Oral Capsule generic · RxCUI 388311 | 326 (99%) | 4 | 0 | 0 | 2 |
| carBAMazepine 200 MG 12HR Extended Release Oral Capsule generic · RxCUI 200133 | 326 (99%) | 4 | 0 | 0 | 2 |
| carBAMazepine 300 MG 12HR Extended Release Oral Capsule generic · RxCUI 200131 | 326 (99%) | 4 | 0 | 0 | 2 |
| carBAMazepine 200 MG Chewable Tablet generic · RxCUI 197442 | 214 (65%) | 2 | 0 | 0 | 2 |
| Equetro 100 MG 12HR Extended Release Oral Capsule brand · RxCUI 672908 | 18 (5%) | 4 | 0 | 2 | 2 |
| Equetro 200 MG 12HR Extended Release Oral Capsule brand · RxCUI 672910 | 18 (5%) | 4 | 0 | 2 | 2 |
| Equetro 300 MG 12HR Extended Release Oral Capsule brand · RxCUI 672909 | 18 (5%) | 4 | 0 | 2 | 2 |
| Carbatrol 100 MG 12HR Extended Release Oral Capsule brand · RxCUI 404742 | 3 (1%) | 2 | 0 | 0 | 0 |
| Carbatrol 200 MG 12HR Extended Release Oral Capsule brand · RxCUI 308977 | 3 (1%) | 2 | 0 | 0 | 0 |
| Carbatrol 300 MG 12HR Extended Release Oral Capsule brand · RxCUI 313931 | 3 (1%) | 2 | 0 | 0 | 0 |
| Tegretol 100 MG in 5 mL Oral Suspension brand · RxCUI 308971 | 3 (1%) | 1 | 0 | 0 | 0 |
| Tegretol 200 MG Oral Tablet brand · RxCUI 308972 | 3 (1%) | 1 | 0 | 0 | 0 |
| Tegretol XR 100 MG 12HR Extended Release Oral Tablet brand · RxCUI 866303 | 3 (1%) | 1 | 0 | 0 | 0 |
| Tegretol XR 200 MG 12HR Extended Release Oral Tablet brand · RxCUI 866305 | 3 (1%) | 1 | 0 | 0 | 0 |
| Tegretol XR 400 MG 12HR Extended Release Oral Tablet brand · RxCUI 866307 | 3 (1%) | 1 | 0 | 0 | 0 |
Counts are formularies (of 328) in the CMS file that list the form, and how many of those apply prior authorization (PA), step therapy (ST) or a quantity limit (QL). Many plans share one formulary, so plan counts in a county will differ.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.